New York court dismisses most of Teva claims against Mexican drugmakers | The Times of Israel
Teva Reports First Quarter 2022 Financial Results | Business Wire
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
Teva reports positive results from pivotal Phase III study to evaluate hydrocodone bitartrate extended-release tablets (CEP-33237) - Drug Target Review